A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Latest Information Update: 07 May 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 13 Dec 2023 Number of treatment arms are decreased from 3 to 1 by the merger of 3 arms into 1, and Ipilimumab is removed from the treatments. Study design is changed from randomized, double blind, parallel to open label, non-randomized, single-group assignment.
- 13 Dec 2023 Planned number of patients changed from 45 to 20.
- 13 Dec 2023 Planned End Date changed from 1 Mar 2027 to 1 Mar 2029.